<DOC>
	<DOCNO>NCT02448381</DOCNO>
	<brief_summary>To evaluate use SGX301 , topical photosensitizing agent , treat patient patch/plaque phase cutaneous T-cell lymphoma ( mycosis fungoides ) .</brief_summary>
	<brief_title>FLASH Fluorescent Light Activated Synthetic Hypericin Clinical Study : Topical SGX301 ( Synthetic Hypericin ) Treatment Cutaneous T-Cell Lymphoma ( Mycosis Fungoides )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Hypericin</mesh_term>
	<criteria>Subjects must clinical diagnosis CTCL ( mycosis fungoides ) , Stage IA , Stage IB , Stage IIA . Subjects must minimum three ( 3 ) evaluable , discrete lesion . Subjects must willing refrain sunbathe duration study . History sun hypersensitivity photosensitive dermatosis include porphyria , systemic lupus erythematosus , Sj√∂gren 's syndrome , xeroderma pigmentosum , polymorphous light eruption radiation therapy within 30 day enrol . Pregnancy mother breast feeding . Males female willing use effective contraception . Unhealed sunburn . Subjects receive topical steroid topical treatment CTCL within 2 week . Subjects receive systemic steroid , nitrogen mustard , psoralen UVA radiation therapy ( PUVA ) , narrow band UVB light therapy ( NBUVB ) carmustine ( BCNU ) systemic therapy CTCL within 3 week enrollment . Subjects significant history systemic immunosuppression due drug infection HIV HTLV 1 . Subjects take investigational drug drug abuse within 30 day entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>CTCL</keyword>
	<keyword>Mycosis fungoides</keyword>
	<keyword>Hypericin</keyword>
	<keyword>SGX301</keyword>
	<keyword>MF</keyword>
</DOC>